TGFBI and neoplasm: The overall (Fig. 2h) and progression-free (Fig. 2i) survival was lower for patients whose CRC tumours had high TGFBI staining in a clinically well-annotated TMA compared with those with low levels of TGFBI, as determined by Kaplan–Meier survival analysis.